Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Profound Medical ( (TSE:PRN) ) has issued an update.
Profound Medical has announced its participation in two upcoming investor conferences in February, where management will hold a series of one-on-one meetings with institutional investors at the Lake Street Life-Sciences Invitational in Scottsdale, Arizona, and the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. While no webcasts will be available due to the meeting formats, the events underscore the company’s ongoing efforts to deepen engagement with the investment community and highlight the commercial progress and broader therapeutic potential of its TULSA-PRO and Sonalleve platforms across prostate and women’s health markets.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
The score is held back primarily by persistent heavy losses and large cash burn despite strong revenue growth and improving gross margins. Technicals are supportive with a clear uptrend, and recent earnings commentary and events point to improving commercial traction and strengthened liquidity, but financing/dilution risk and lack of profitable valuation anchors keep the overall score in the mid-range.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its flagship TULSA-PRO system supports the TULSA Procedure, a minimally invasive, radiation-free prostate treatment designed to preserve urinary continence and sexual function while treating a broad spectrum of prostate diseases. The company also markets the Sonalleve platform for non-invasive treatment of uterine fibroids, adenomyosis, certain bone metastases, desmoid tumors, and osteoid osteoma, with regulatory clearances in North America, Europe, and China and ongoing exploration of additional oncologic applications.
Average Trading Volume: 20,371
Technical Sentiment Signal: Buy
Current Market Cap: C$384.7M
For detailed information about PRN stock, go to TipRanks’ Stock Analysis page.